iX Biopharma Ltd.(SG:42C)
S$0.46+0.01 (+1.10%)
SG:42C
iX Biopharma Ltd. financials statements
S$0.46
At close:+0.01 (+1.10%)
Want to see SG:42C full AI Analyst Report?
iX Biopharma Ltd. (42C) Ratios
26 Followers
iX Biopharma Ltd. Ratios
SG:42C's free cash flow for Q4 2025 was S$-2.72M. For the 2025 fiscal year, SG:42C's free cash flow was decreased by S$-88.00K and operating cash flow was S$-2.63M. See a summary of the company’s cash flow.
| Ratios | Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.86 | 0.47 | 0.89 | 1.53 | 2.14 |
| Quick Ratio | 1.74 | 0.37 | 0.71 | 1.40 | 2.03 |
| Cash Ratio | 1.47 | 0.10 | 0.24 | 0.91 | 1.72 |
| Solvency Ratio | -0.69 | -0.85 | -0.97 | -0.96 | -0.40 |
| Operating Cash Flow Ratio | -0.80 | -0.42 | -0.89 | -1.07 | 0.40 |
| Short-Term Operating Cash Flow Coverage | -1.52 | -0.92 | -2.63 | -2.78 | 0.95 |
| Net Current Asset Value | S$ 8.13M | S$ -6.71M | S$ -3.70M | S$ 1.90M | S$ 8.07M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.22 | 0.52 | 0.36 | 0.17 | 0.15 |
| Debt-to-Equity Ratio | 0.38 | 16.17 | 1.20 | 0.27 | 0.22 |
| Debt-to-Capital Ratio | 0.27 | 0.94 | 0.55 | 0.21 | 0.18 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.80 | 0.33 | 0.03 | 0.04 |
| Financial Leverage Ratio | 1.68 | 30.92 | 3.37 | 1.57 | 1.44 |
| Debt Service Coverage Ratio | -1.50 | -2.04 | -3.24 | -2.78 | -0.96 |
| Interest Coverage Ratio | -13.86 | -19.58 | -16.71 | -31.04 | 6.14 |
| Debt to Market Cap | 0.02 | 0.40 | 0.21 | 0.05 | 0.03 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Net Debt to EBITDA | 1.01 | -0.56 | -0.40 | 0.26 | 3.20 |
| Profitability Margins | |||||
| Gross Profit Margin | 35.52% | 26.26% | 17.59% | 39.24% | 85.41% |
| EBIT Margin | -139.52% | -126.42% | -160.14% | -159.56% | -27.08% |
| EBITDA Margin | -128.89% | -115.42% | -145.58% | -143.85% | -19.72% |
| Operating Profit Margin | -139.52% | -80.92% | -123.98% | -142.25% | 8.62% |
| Pretax Profit Margin | -116.50% | -130.55% | -167.56% | -164.15% | -28.49% |
| Net Profit Margin | -116.64% | -130.57% | -181.14% | -162.61% | -31.95% |
| Continuous Operations Profit Margin | -116.64% | -130.57% | -181.14% | -162.61% | -31.95% |
| Net Income Per EBT | 100.11% | 100.01% | 108.10% | 99.06% | 112.17% |
| EBT Per EBIT | 83.51% | 161.34% | 135.15% | 115.40% | -330.56% |
| Return on Assets (ROA) | -30.89% | -89.87% | -73.81% | -38.57% | -16.12% |
| Return on Equity (ROE) | -51.92% | -2778.36% | -248.71% | -60.65% | -23.29% |
| Return on Capital Employed (ROCE) | -60.23% | -272.67% | -102.00% | -47.38% | 6.00% |
| Return on Invested Capital (ROIC) | -44.68% | -94.36% | -73.00% | -39.78% | 5.13% |
| Return on Tangible Assets | -30.89% | -92.07% | -75.33% | -39.03% | -16.32% |
| Earnings Yield | -2.27% | -72.50% | -48.50% | -13.81% | -3.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.48 | 4.01 | 4.40 | 4.37 | 25.93 |
| Payables Turnover | 1.06 | 1.33 | 3.90 | 9.10 | 9.38 |
| Inventory Turnover | 3.70 | 6.21 | 3.56 | 3.76 | 2.32 |
| Fixed Asset Turnover | 0.96 | 1.16 | 0.78 | 0.72 | 1.86 |
| Asset Turnover | 0.26 | 0.69 | 0.41 | 0.24 | 0.50 |
| Working Capital Turnover Ratio | 3.57 | -2.79 | 3.96 | 0.92 | 1.96 |
| Cash Conversion Cycle | -140.17 | -125.11 | 91.85 | 140.57 | 132.62 |
| Days of Sales Outstanding | 104.98 | 91.07 | 82.94 | 83.58 | 14.08 |
| Days of Inventory Outstanding | 98.54 | 58.76 | 102.57 | 97.12 | 157.47 |
| Days of Payables Outstanding | 343.69 | 274.94 | 93.65 | 40.13 | 38.93 |
| Operating Cycle | 203.52 | 149.84 | 185.50 | 180.70 | 171.55 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.00 | -0.01 | -0.01 | 0.00 |
| Free Cash Flow Per Share | -0.01 | -0.00 | -0.01 | -0.01 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | -69.19 | -18.70 | -22.99 | -11.02 | 15.62 |
| Capital Expenditure Coverage Ratio | -69.19 | -18.70 | -22.99 | -11.02 | 15.62 |
| Operating Cash Flow Coverage Ratio | -1.37 | -0.64 | -1.26 | -1.77 | 0.71 |
| Operating Cash Flow to Sales Ratio | -1.16 | -0.48 | -1.10 | -1.30 | 0.22 |
| Free Cash Flow Yield | -2.29% | -28.30% | -30.73% | -12.00% | 2.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -43.98 | -1.38 | -2.06 | -7.24 | -26.75 |
| Price-to-Sales (P/S) Ratio | 51.40 | 1.80 | 3.73 | 11.77 | 8.55 |
| Price-to-Book (P/B) Ratio | 22.88 | 38.32 | 5.13 | 4.39 | 6.23 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -43.64 | -3.53 | -3.25 | -8.33 | 42.08 |
| Price-to-Operating Cash Flow Ratio | -44.27 | -3.72 | -3.40 | -9.09 | 39.39 |
| Price-to-Earnings Growth (PEG) Ratio | 1.55 | 0.08 | -0.17 | -0.07 | 0.55 |
| Enterprise Value Multiple | -38.87 | -2.12 | -2.96 | -7.93 | -40.15 |
| Enterprise Value | 343.30M | 19.02M | 25.68M | 67.42M | 113.92M |
| EV to EBITDA | -38.87 | -2.12 | -2.96 | -7.93 | -40.15 |
| EV to Sales | 50.09 | 2.45 | 4.31 | 11.40 | 7.92 |
| EV to Free Cash Flow | -42.53 | -4.81 | -3.76 | -8.07 | 38.97 |
| EV to Operating Cash Flow | -43.14 | -5.06 | -3.92 | -8.80 | 36.48 |
| Tangible Book Value Per Share | 0.02 | 0.00 | 0.01 | 0.02 | 0.03 |
| Shareholders’ Equity Per Share | 0.02 | 0.00 | 0.01 | 0.02 | 0.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.08 | 0.01 | -0.12 |
| Revenue Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Net Income Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Tax Burden | 1.00 | 1.00 | 1.08 | 0.99 | 1.12 |
| Interest Burden | 0.84 | 1.03 | 1.05 | 1.03 | 1.05 |
| Research & Development to Revenue | 0.36 | 0.21 | 0.29 | 0.48 | 0.16 |
| SG&A to Revenue | 1.39 | 0.86 | 0.72 | 0.99 | 0.51 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | -0.14 | 0.14 | 0.10 |
| Income Quality | 1.00 | 0.37 | 0.61 | 0.80 | -0.68 |
Currency in SGD

